Reactions to Learning Amyloid and Tau Results in Adults at Risk for Alzheimer's Dementia

Official Summary

This is a prospective, single-cohort, single-center, observational study to assess if learning one's Alzheimer's disease biomarker test result impacts longitudinal psychosocial, behavioral, and neuropsychological outcomes, and to identify factors that moderate and mediate these outcomes. Participants enrolled in this study are requested to complete surveys at four timepoints after learning their Alzheimer's biomarker test results.

Study Design

• Study Type: OBSERVATIONAL
• Enrollment: 240 participants

Interventions

• OTHER: Disclose amyloid, tau results — Release of results from investigational agents conducted under IND 107114, IND 166860, and IND 134516
• OTHER: Follow-up Assessments — self-report psychosocial and behavioral questionnaires

Primary Outcomes

• Impact of Neuroimaging in Alzheimer's Disease (INI-AD) Score (1 month, 6 months, 12 months, 18 months)
• Stigma Impact Scale (SIS) Score (1 month, 6 months, 12 months, 18 months)
• Control, Autonomy, Self-Realization, and Pleasure (CASP-12) (baseline, 1 month, 6 months, 12 months, 18 months)
• Future Time Perspective Scale (baseline, 1 month, 6 months, 12 months, 18 months)

Secondary Outcomes

• Willingness to Prevent AD (baseline, 1 month, 6 months, 12 months, 18 months)
• Willingness to Prevent AD: Over the counter, prescription, clinical trial items (baseline, 1 month, 6 months, 12 months, 18 months)
• Exercise Vital Sign Tool: Minutes per Week of Moderate or Vigorous Exercise (baseline, 1 month, 6 months, 12 months, 18 months)
• Cognitive & Leisure Activity Scale (CLAS) (baseline, 1 month, 6 months, 12 months, 18 months)
• 6-item questionnaire for Mediterranean diet (baseline, 1 month, 6 months, 12 months, 18 months)

Trial Locations

• University of Wisconsin, Madison, Wisconsin, United States

More Alzheimer Disease Trials

View all Alzheimer Disease clinical trials